Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions

Table 2 Cooperative group trial of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission

Cooperative group	Relapse rate			Disease free survival			Overall survival
	Allo	Auto	CC	Allo	Auto	CC	Allo	Auto	CC
EORTC/GIMEMA AML-8	24%1	41%	57%	55%1	48%1	30%	59%	56%	46%
GOELAM	37%	45%	55%	49%	48%	43%	55%	52%	58%
ECOG/CALGB/SWOG	29%1	48%	61%	43%	34%	34%	46%	43%	52%1
EORTC/GIMEMA AML-10	30%1	52%	-	52%1	42%	-	58%	50%	-
UK MRC AML-1023	36%1	52%		50%1	42%		55%	42%
HOVON-SAKK3	32%1	59%		48%1	37%		54%	46%

¹Represents statistically significant and favorable outcome with the treatment modality;

²The 4-year relapse rate, disease free survival and overall survival shown in all studies, except the UK-MRC AML-10 which reported 7-year outcomes;

³All studies designed to compare outcomes between allograft vs autograft vs consolidation chemotherapy except the UK MRC AML-10 and HOVON-SAKK trial which did not differentiate between autograft and chemotherapy. Allo: Allogeneic transplantation; auto: Autologous transplantation; CC: Consolidation chemotherapy.